Answers are grounded in this paper and cite their sources.
Purpose Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a critical mechanism in cancer biology and therapeutic resistance. This study aims to investigate the clinical relevance of key ferroptosis regulators, including HO-1, GPX4, and SLC7A11, in patients with colorectal cancer (CRC). Methods A total of 103 CRC tissue samples were analysed. Gene expression levels of HO-1, GPX4, and SLC7A11 were assessed, and their associations with clinicopathological features were evaluated. Iron concentrations were quantified using inductively coupled plasma optical emission spectrometry (ICP-OES). Associations between biomarker expression, iron levels, and clinicopathological characteristics were analysed. Results HO-1 and GPX4 expression were significantly higher in patients aged ≤ 69 years compared with older patients (p = 0.027 and p = 0.008, respectively). HO-1 expression was significantly associated with microsatellite stability (p = 0.026). Also, SLC7A11 expression was significantly associated with tumour site (p = 0.037), with higher expression in proximal colon tumours, and was also associated with tissue iron levels (p = 0.031). Significant associations were identified between HO-1 and GPX4 expression (p < 0.001) and a marginal association between HO-1 and SLC7A11 (p = 0.062). Conclusion Ferroptosis-related genes are associated with clinicopathological features and tissue iron levels in colorectal cancer. The relationships among HO-1, GPX4, and SLC7A11 suggest interactions between iron metabolism, oxidative stress, and ferroptosis pathways, highlighting potential therapeutic targets in CRC.
No takes yet. Share an insight, caveat, or question.
Moetamedirad et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: